CSIR: The Council of Scientific and Industrial Research (CSIR), India’s apex scientific research organisation and Tata Medical and Diagnostics Ltd (Tata MD), the new healthcare venture from the Tata Group have announced a significant partnership to ramp up the COVID-19 testing capacity across tier II and III towns and rural areas across India. The capacity will help to manage any future surge in the testing requirements. The initiative will utilise CSIR’s network of labs across India. The RT-PCR test will be done using the Tata MD CHECK SARS-CoV-2 test kits that are powered by FELUDA technology from CSIR-IGIB.
Dr Shekhar C Mande, Director General, CSIR said “Apart from vaccination, rapid testing and isolation of SARS-CoV-2 positive persons has emerged as the best strategy in combating Covid-19. This capacity will augment the national capacity to test for COVID and detect it locally.”
Mr. Girish Krishnamurthy, CEO and MD of Tata MD said “By partnering with CSIR’s network of labs, we are confident that we can quickly augment testing capacity using faster and scalable methods. This will enhance the ability of any state and district administrations to ensure wider availability and easier access to testing on an on-going basis.” This partnership between CSIR is aimed at expanding the testing capacity via the vast network of 37 CSIR labs spread across the country. The first such lab is being launched in Dehradun in Uttarakhand.
Tata MD provides an end-to-end and reliable COVID-19 testing solution-
Tata MD CHECK SARS-CoV-2 test: A paper strip based RT-PCR CRISPR test, which has been approved by ICMR.
Tata MD Automated testing solution- Tata MD CHECK automated testing solution can increase testing capacity by thousands with no cross-contamination.
Tata MD Mobile Testing Labs- Tata MD is also deploying a proprietary 3-room design mobile testing lab can conduct end-to-end, on-site COVID-19 testing to increase the testing capacity in the state.